ChromaDex, a US-based phytochemicals and ingredient technology company, has received an undisclosed amount of equity financing from DSM Venturing, the corporate venture arm of Netherlands-based life sciences and material sciences company Royal DSM.
Frank Jaksch, chief executive officer and co-founder of ChromaDex, said: “It is with great pride and enthusiasm that we welcome DSM as a strategic investor in ChromaDex. We believe the investment demonstrates their confidence in the future of ChromaDex as well as our unique business model of acquiring and commercializing novel ingredient technologies.”
Pieter Wolters, managing director DSM Venturing, said: “We are pleased to invest in ChromaDex and thereby support Frank Jaksch and the entire ChromaDex team in the expansion of their business.”